This present application relates generally to prostheses and surgical methods, and specifically to tubular prostheses, including endovascular stent-grafts, and surgical techniques for using the prostheses to maintain patency of body passages such as blood vessels, and treating aneurysms.
Endovascular prostheses are sometimes used to treat aortic aneurysms. Such treatment includes implanting a stent or stent-graft within the diseased vessel to bypass the anomaly. An aneurysm is a sac formed by the dilation of the wall of the artery. Aneurysms may be congenital, but are usually caused by disease or, occasionally, by trauma. Aortic aneurysms include abdominal aortic aneurysms (“i”), which form between the renal arteries and the iliac arteries, and thoracic aortic aneurysms (“TAAs”), which may occur in one or more of the descending aorta, the ascending aorta, and the aortic arch.
Some applications of the present invention provide endovascular stent-grafts characterized by high physiological compliance. Such high physiological compliance minimizes the effect of the stent-grafts on the pulse profile of a blood vessel in which the stent-grafts are implanted, such as the aorta. Large-caliber arteries, in particular the aorta, provide the majority of arterial vascular compliance. The aorta and the branching large blood vessels thus act as a mechanical capacitor that expands during systole and contracts during diastole. Conventional endovascular stent-grafts often comprise substantially non-compliant graft materials, and even when such stent-grafts utilize relatively flexible medical fabrics, the stent-grafts are usually essentially fully expanded under diastolic arterial pressure. As a result, conventional stent-grafts substantially do not radially pulsate with the systolic cycle. Therefore, implantation of conventional stent-grafts results in the replacement of a large portion of a compliant aorta with a non- or low-compliant prosthesis. Conventional endovascular stent-grafts thus generally change the aortic pulse profile. Such a reduction in the overall vascular compliance may have deleterious cardiovascular effects, by increasing the load of the heart and/or decreasing the effectiveness of propagation of the systolic pulse from the heart into the smaller-caliber vasculature.
Some applications of the present invention provide endovascular stent-grafts that have beneficial effects on the peripheral vascular load, while using well-proven, gold-standard, medical-grade textiles and metallic alloys. The stent-grafts are configured to provide mechanical compliance that maintains (or, in some cases, even restores) the native, healthy, physiological compliance of the arterial segment in which the stent-grafts are implanted.
In some applications of the present invention, an endovascular stent-graft comprises a generally tubular body, which is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. The body comprises a flexible stent member and a tubular fluid flow guide. The tubular flow guide comprises a graft material, which is generally non- or minimally-elastic. The body includes a compliance-restoration body portion that extends axially along a portion of the body. When the body is in the radially-expanded deployment state, the compliance-restoration body portion is (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, typically by blood during diastole in an adult human, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, typically by blood during systole in an adult human. The greatest systolic outer radius is typically at least 5% greater than the greatest diastolic outer radius, such as at least 10%, e.g., 15%, greater than greatest diastolic outer radius. This increase in outer radius at greater internal pressure occurs because the stent is heat-set to have a diameter that is substantially (e.g., 5%-20%) less than the graft's fully-expanded (i.e., without folds) diameter, and the stent has the appropriate radial compliance such that the entire stent-graft substantially changes its radius between a state in which the stent-graft is internally pressurized by a nominal hydrostatic diastolic pressure and a state in which the stent-graft is internally pressurized by a nominal hydrostatic systolic pressure.
For example, the stent member may comprise a highly elastic (e.g. flexible stainless steel) or a superelastic (e.g. Nitinol) alloy that is heat-set to have a first relaxed outer diameter, e.g., 23 mm, along the compliance-restoration body portion when the body is not internally pressurized by fluid. The tubular flow guide is configured to have a greater, second outer diameter, e.g., 30 mm, when internally pressurized to systolic pressure, e.g., 120 mmHg. When pressurized by fluid having a diastolic pressure, e.g., 80 mmHg, the compliance-restoration body portion assumes a diastolic outer diameter that is slightly larger than the first relaxed outer diameter, e.g., between 26 and 27 mm. When pressurized by the fluid having systolic pressure, e.g., 120 mmHg, the compliance-restoration body portion assumes a systolic outer diameter equal to the second outer diameter, e.g., 30 mm, as limited by the diameter of the non-compliant graft material. For some applications, proximal and distal end-portions of the stent-graft have respective relaxed outer diameters that are greater than the first relaxed outer diameter, which may help provide good fixation and sealing with the blood vessel wall.
In contrast, conventional thoracic aortic stent-grafts often comprise a Nitinol stent skeleton having a heat-set diameter of 32 mm and a tubular woven PET graft cylinder having a diameter of 30 mm, sewn to the stent skeleton. Such conventional stent-grafts may have a relaxed diameter of 30 mm, and do not allow for further expansion during systole. Conventional stent-grafts thus do not provide the radial compliance provided by some applications of the present invention.
In some applications of the present invention, a variable-length endovascular stent-graft comprises a generally tubular body, which comprises a fluid flow guide and a plurality of structural stent elements attached to at least a portion of the fluid flow guide. The body includes a variable-length section that extends axially along a portion of body. The body, including the variable-length section, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state. The variable-length section, while radially-expanded in the deployment state, is configured to enable a change in an axial length thereof of at least 5 mm.
This change in axial length enables the stent-graft to accommodate any elongation of the blood vessel between the ends of the stent-graft that may occur after implantation of the stent-graft. Such elongation often occurs after implantation of a stent-graft. Because the stent-graft excludes the aneurysm from the blood circulation, the aneurysm thromboses, decomposes and shrinks, causing the blood vessel to become longer and narrower. Typically, such elongation occurs over a long period of time, and the stent-graft provides long-term accommodation of the elongation. Such accommodation decreases the risk of the stent-graft becoming dislodged, and decreases the risk of endoleak. Alternatively or additionally, this change in axial length provides axial compliance for reducing vascular resistance, similar to the radial compliance described above.
When the body is in the radially-expanded deployment state, the variable-length section is configured to assume an axially-shortest state thereof, in which state typically one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state; for some applications, the variable-length section has no structural-stent-element-free portions when in its axially-shortest state. Typically, the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation as the axial-length changes.
Typically, the body is configured such that elasticity of graft material of the fluid flow guide provides less than 5% of a change in an axial length of the variable-length section. In other words, the change in the axial length of the variable-length section is not primarily enabled by stretching of the graft material of the fluid flow guide.
There is therefore provided, in accordance with an application of the present invention, apparatus including an endovascular stent-graft, which includes a generally tubular body, which body (a) is configured to assume a radially-compressed delivery state and a radially-expanded deployment state, and (b) includes:
a flexible stent member; and
a tubular fluid flow guide, which includes a graft material, and is attached to the stent member,
wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the stent member and a portion of the fluid flow guide,
wherein, when the body is in the radially-expanded deployment state, the compliance-restoration body portion is (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, and
wherein the greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius, such as at least 10% greater than the greatest diastolic outer radius.
For some applications, the fluid flow guide of the compliance-restoration body portion is shaped so as to be expandable to a maximum greatest outer radius equal to the greatest systolic outer radius of the compliance-restoration body portion, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius.
For some applications, the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest diastolic outer radius when the body is internally pressurized by the fluid having the pressure of 80 mmHg.
For any of the applications described above, when the body is in the radially-expanded deployment state, the compliance-restoration body portion may be characterized by a greatest relaxed outer radius when the body is not internally pressurized by fluid, which greatest relaxed outer radius is no more than 95% of the greatest diastolic outer radius. For some applications, the stent member is heat-set to cause the compliance-restoration body portion to assume the greatest relaxed outer radius when unconstrained.
For any of the applications described above, the graft material may include a woven graft.
For any of the applications described above, the graft material of the portion of the fluid flow guide may be at least partially folded when the body is in the radially-expanded deployment state and is internally pressured by the fluid of having the pressure of 80 mmHg.
For any of the applications described above, the fluid flow guide, if not attached to the stent member, may be configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being no more than 10% greater than the first perimeter.
For any of the applications described above, the fluid flow guide, if not attached to the stent member, may be configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being between 0.5% and 5% greater than the first perimeter.
For any of the applications described above, the stent member may include a plurality of structural stent elements that are indirectly connected to one another by the fluid flow guide.
For any of the applications described above, the stent member may include a plurality of interconnected structural stent elements.
For any of the applications described above, the greatest systolic outer radius may be no more than 30% greater than the greatest diastolic outer radius.
For any of the applications described above, the greatest diastolic outer radius may be between 7.5 mm and 25 mm, when the body is in the radially-expanded deployment state.
For any of the applications described above, the greatest systolic outer radius may be between 8.5 mm and 30 mm, when the body is in the radially-expanded deployment state.
For any of the applications described above, the body may further includes distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed,
when the body is in the radially-expanded deployment state, the distal and proximal portions may be (a) characterized by greatest diastolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to greatest systolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by fluid having a pressure of 120 mmHg,
the greatest systolic distal-end-portion outer radius may be less than 2% greater than the greatest diastolic distal-end-portion outer radius, and
the greatest systolic proximal-end-portion outer radius may be less than 2% greater than the greatest diastolic proximal-end-portion outer radius.
For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and respective greatest radii of the distal and the proximal portions may be each at least 5% greater than a greatest relaxed outer radius of the compliance-restoration body portion, when the body is unconstrained in the radially-expanded deployment state.
For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and respective greatest radii of the distal and the proximal portions may be each at least 5% greater than the greatest diastolic outer radius, when the body is in the radially-expanded deployment state.
For any of the applications described above, the body may further include distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed, and a greatest outer radius of the distal portion, when unconstrained, may be between 2 and 10 mm greater than the greatest systolic outer radius, when the body is in the radially-expanded deployment state.
For any of the applications described above, the graft material may include a material selected from the group of materials consisting of: Polyethylene terephthalate (PET), Dacron, Polytetrafluoroethylene (PTFE), ePTFE, and a combination of two or more of these materials.
For any of the applications described above, the stent member may include a superelastic alloy.
For any of the applications described above, the stent-graft may be configured to self-expand from the delivery state to the deployment state.
For any of the applications described above:
the flexible stent member may include a plurality of structural stent elements attached to at least a portion of the fluid flow guide,
the body may include a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,
the body, including the variable-length section, may be configured to assume the radially-compressed delivery state and the radially-expanded deployment state,
wherein, when the body is in the radially-expanded deployment state, the variable-length section may be configured to:
There is further provided, in accordance with an application of the present invention, apparatus including an endovascular stent-graft, which includes a generally tubular body, which body includes:
a fluid flow guide, which includes a graft material; and
a plurality of structural stent elements attached to at least a portion of the fluid flow guide,
wherein the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,
wherein the body, including the variable-length section, is configured to assume a radially-compressed delivery state and a radially-expanded deployment state,
wherein, when the body is in the radially-expanded deployment state, the variable-length section is configured to:
For some applications, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions, when the variable-length section is in the axially-shortest state when the body is in the radially-expanded deployment state.
For some applications, the body is configured such that elasticity of the graft material provides less than 5% of the change in the axial length of the variable-length section.
For some applications, the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation during the change in axial length.
For some applications, the variable-length section is configured such that the enabled change in the axial length is no more than 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.
For any of the applications described above, the variable-length section may be configured such that the enabled change in the axial length is equal to at least 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.
For any of the applications described above, a surface coverage ratio of the one or more of the structural stent elements of the variable-length section on the fluid flow guide may be equal to at least 5% when the variable-length section is in the axially-shortest state when the body is in the radially-expanded deployment state.
For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to undergo the change in the axial length in response to a change in fluid pressure within the fluid flow guide.
For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to undergo an increase in the axial length, and not a decrease in the axial length.
For any of the applications described above, when the body is in the radially-expanded deployment state, the variable-length section may be configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length.
For any of the applications described above, the variable-length section may be configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide.
For any of the applications described above, the variable-length section may be configured to undergo (a) an increase in the axial length in response to a decrease in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to an increase in the fluid pressure within the fluid flow guide.
For any of the applications described above, the variable-length section may be configured such that during a 5 mm change in the axial length, an average wall thickness of the graft material changes by no more than 15%.
For any of the applications described above, the variable-length section may be configured to assume a folded position at least when the variable-length section is in the axially-shortest state, in which folded position a first longitudinal subsection of the fluid flow guide is radially sandwiched between second and third longitudinal subsections of the fluid flow guide.
For any of the applications described above, the variable-length section may be configured such that in the folded position the second longitudinal subsection radially surrounds the first longitudinal subsection, and at least one of the one or more of the structural stent elements of the variable-length section is attached to the second longitudinal subsection. For some applications, the variable-length section is configured such that in the folded position the first longitudinal subsection radially surrounds the third longitudinal subsection, and at least one of the one or more of the structural stent elements of the variable-length section is attached to the third longitudinal subsection. For some applications, the variable-length section is configured such that none of the structural stent elements of the body is attached to the first longitudinal subsection.
For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge at least partially around a perimeter of an axial site on the variable-length section, which radially-outward bulge includes the one or more of the structural elements of the variable-length section. For some applications, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. For some applications, the variable-length section, when in an axially-longest state, is not shaped so as to define the bulge.
For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-inward indentation at least partially around a perimeter of an axial site on the variable-length section, which indentation includes the one or more of the structural elements of the variable-length section. For some applications, the variable-length section is configured such that a radial dimension of the indentation decreases as the axial length of the variable-length section increases. For some applications, the variable-length section, when in an axially-longest state, is not shaped so as to define the indentation.
For any of the applications described above, the variable-length section may be configured such that when the variable-length section undergoes the change in the axial length, a proximal end of the variable-length section rotates with respect to a distal end of the variable-length section.
For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one single-sided helix, which includes the one or more of the structural elements. For some applications, the variable-length section is configured such that a step size of the at least one-single-sided helix increases as the axial length of the variable-length section increases.
For any of the applications described above, the variable-length section may be shaped so as to define, at least when the variable-length section is in the axially-shortest state, at least one right-handed helix and at least one left-handed helix, which helices include the one or more of the structural elements. For some applications, the variable-length section is configured such that respective step sizes of the right- and left-handed helices either both increase, or both decrease as axial length of the variable-length section increases.
For any of the applications described above:
the body may include a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the structural stent elements and a portion of the fluid flow guide,
when the body is in the radially-expanded deployment state, the compliance-restoration body portion may be (a) characterized by a greatest diastolic outer radius when the body is internally pressurized by fluid having a pressure of 80 mmHg, and (b) radially expandable to a greatest systolic outer radius when the body is internally pressurized by fluid having a pressure of 120 mmHg, and
the greatest systolic outer radius may be at least 5% greater than the greatest diastolic outer radius.
There is still further provided, in accordance with an application of the present invention, a method including:
providing an endovascular stent-graft, which includes a generally tubular body, which includes a flexible stent member, and a tubular fluid flow guide, which includes a graft material, and is attached to the stent member, wherein the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the stent member and a portion of the fluid flow guide;
transvascularly introducing the stent-graft into a blood vessel of a human subject while the body is in a radially-compressed delivery state; and
thereafter, transitioning the body to a radially-expanded deployment state in the blood vessel, in which state the compliance-restoration body portion is characterized by (a) a greatest diastolic outer radius when the body is internally pressurized by blood of the subject during diastole, and (b) a greatest systolic outer radius when the body is internally pressurized by blood of the subject during systole, which greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius.
For some applications, transitioning the body to the deployment state includes allowing the body to self-expand.
For some applications, the greatest systolic outer radius is at least 10% greater than the greatest diastolic outer radius.
For some applications, providing the stent-graft includes providing the stent-graft in which the fluid flow guide of the compliance-restoration body portion is shaped so as to be expandable to a maximum greatest outer radius equal to the greatest systolic outer radius of the compliance-restoration body portion, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius.
For some applications, providing the stent-graft includes providing the stent-graft in which the fluid flow guide, if not attached to the stent member, is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively, the second perimeter being no more than 10% greater than the first perimeter.
For some applications:
the body further includes distal and proximal portions, longitudinally between which the compliance-restoration body portion is disposed,
when the body is in the radially-expanded deployment state, the distal and proximal portions are characterized by (a) greatest diastolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by the blood during diastole, and (b) greatest systolic distal- and proximal-end-portion radii, respectively, when the body is internally pressurized by the blood during systole,
the greatest systolic distal-end-portion outer radius is less than 2% greater than the greatest diastolic distal-end-portion outer radius, and
the greatest systolic proximal-end-portion outer radius is less than 2% greater than the greatest diastolic proximal-end-portion outer radius.
For some applications, the greatest systolic outer radius is no more than 30% greater than the greatest diastolic outer radius.
For some applications:
the flexible stent member includes a plurality of structural stent elements attached to at least a portion of the fluid flow guide,
the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,
the body, including the variable-length section, is configured to assume the radially-compressed delivery state and the radially-expanded deployment state,
after the body is transitioned to the radially-expanded deployment state, the variable-length section is configured to enable a change in an axial length thereof of at least 5 mm, and
if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.
There is additionally provided, in accordance with an application of the present invention, a method including:
providing an endovascular stent-graft, which includes a generally tubular body, which includes a fluid flow guide, which includes a graft material, and a plurality of structural stent elements attached to at least a portion of the fluid flow guide, wherein the body includes a variable-length section, which extends axially along a portion of the body, and which includes one or more of the structural stent elements and a portion of the fluid flow guide,
transvascularly introducing the stent-graft into a blood vessel of a human subject while the body, including the variable-length section, is in a radially-compressed delivery state; and
thereafter, transitioning the body to a radially-expanded deployment state in the blood vessel, in which state the variable-length section is configured to enable a change in an axial length thereof of at least 5 mm,
wherein, if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5% of a greatest outer diameter of the fluid flow guide along the variable-length section when in its axially-shortest state.
For some applications, if the variable-length section assumes an axially-shortest state thereof while the body is in the radially-expanded deployment state, the one or more of the structural stent elements are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions.
For some applications, providing the stent-graft includes providing the stent-graft in which the body is configured such that elasticity of the graft material provides less than 5% of the change in the axial length of the variable-length section.
For some applications, providing the stent-graft includes providing the stent-graft in which the variable-length section is configured such that the structural stent elements thereof do not undergo plastic deformation during the change in axial length.
For some applications, providing the stent-graft includes providing the stent-graft in which the variable-length section is configured such that the enabled change in the axial length is no more than 10% of a greatest outer diameter of the fluid flow guide along the variable-length section when the variable-length section is in the axially-shortest state.
For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to undergo the change in the axial length in response to a change in fluid pressure within the fluid flow guide.
For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to undergo an increase in the axial length, and not a decrease in the axial length.
For some applications, when the body is in the radially-expanded deployment state, the variable-length section is configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length. For some applications, the variable-length section is configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide.
For some applications, the variable-length section is configured such that during a 5 mm change in the axial length, an average wall thickness of the graft material changes by no more than 15%.
For some applications, the variable-length section is configured to assume a folded position at least when the variable-length section is in the axially-shortest state, in which folded position a first longitudinal subsection of the fluid flow guide is radially sandwiched between second and third longitudinal subsections of the fluid flow guide.
For some applications, the variable-length section is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge at least partially around a perimeter of an axial site on the variable-length section, which radially-outward bulge includes the one or more of the structural elements of the variable-length section.
For some applications, the variable-length section is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-inward indentation at least partially around a perimeter of an axial site on the variable-length section, which indentation includes the one or more of the structural elements of the variable-length section.
For some applications, the body includes a compliance-restoration body portion, which extends axially along a portion of the body, and which includes a portion of the structural stent elements and a portion of the fluid flow guide; and after the body is transitioned to the radially-expanded deployment state, the compliance-restoration body portion is characterized by (a) a greatest diastolic outer radius when the body is internally pressurized by blood flow of the subject during diastole, and (b) a greatest systolic outer radius when the body is internally pressurized by blood of the subject during systole, which greatest systolic outer radius is at least 5% greater than the greatest diastolic outer radius.
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Body 22 comprises a flexible stent member 24, and a tubular fluid flow guide 26. The fluid flow guide is attached to the stent member, such as by suturing or stitching. The flexible stent member may be attached to an internal and/or an external surface of the fluid flow guide. Optionally, a portion of the structural stent elements may be attached (e.g., sutured) to the internal surface of the fluid flow guide, and another portion to the external surface of the fluid flow guide. Flexible stent member 24 comprises a plurality of structural stent elements 28, which are either indirectly connected to one another by the fluid flow guide (as shown), and/or interconnected with one another (configuration not shown). For some applications, structural stent elements 24 comprise a metal. Alternatively or additionally, the structural stent elements comprise a self-expanding material, such that body 22 (and, optionally, stent-graft 20) is self-expandable.
Alternatively or additionally, the structural stent elements comprise one or more metallic alloys, such as one or more superelastic metal alloys, a shape memory metallic alloy, and/or Nitinol.
Fluid flow guide 26 comprises a graft material, i.e., at least one biologically-compatible substantially blood-impervious flexible sheet. The flexible sheet may comprise, for example, a polyester, a polyethylene (e.g., a poly-ethylene-terephthalate), a polymeric film material (such as a fluoropolymer, e.g., polytetrafluoroethylene), a polymeric textile material (e.g., woven polyethylene terephthalate (PET)), natural tissue graft (e.g., saphenous vein or collagen), Polytetrafluoroethylene (PTFE), ePTFE, Dacron, or a combination of two or more of these materials. The graft material optionally is woven. The graft material of fluid flow guide 26 is generally non- or minimally-elastic.
Typically, stent-graft 20 is configured to self-expand from the delivery state to the deployment state. For example, stent member 24 may be heat-set to cause stent-graft 20 to self-expand from the delivery state to the deployment state.
Body 22 includes a compliance-restoration body portion 34, which extends axially along a portion of body 22, and which comprises a portion of stent member 24 and a portion of fluid flow guide 26. When body 22 is in the radially-expanded deployment state, as shown in
Greatest systolic outer radius RS is typically at least 5% greater than greatest diastolic outer radius RD, such as at least 10% greater than greatest diastolic outer radius RD, e.g., at least 15% greater than greatest diastolic outer radius RD. Alternatively or additionally, greatest systolic outer radius RS is no more than 30% greater than the greatest diastolic outer radius RD. This increase in outer radius at greater internal pressure occurs because the stent is heat-set to have a diameter that is substantially (e.g., 5%-20%) less than the graft's fully-expanded (i.e., without folds) diameter, and the stent has the appropriate radial compliance such that the entire stent-graft substantially changes its radius between a state in which the stent-graft is internally pressurized by a nominal hydrostatic diastolic pressure and a state in which the stent-graft is internally pressurized by a nominal hydrostatic systolic pressure.
For some applications, fluid flow guide 26 of compliance-restoration body portion 34 is shaped so as to be expandable to a maximum greatest outer radius RM equal to greatest systolic outer radius RS of compliance-restoration body portion 34, such that the compliance-restoration body portion is limited by the fluid flow guide from assuming an outer radius that is greater than the maximum greatest outer radius RM. (The outer radius might not otherwise be limited by stent member 24, which is typically highly compliant and deformable, e.g., initially highly elastically deformable and subsequently, plastically deformable.) Typically, maximum greatest outer radius RM of fluid flow guide 26 is greater than the greatest diastolic outer radius of stent member 24, such as at least 5%, at least 10%, or at least 20% greater than greatest diastolic outer radius RD of stent member 24. During diastole, the inward compressive force applied by stent-member 24 is countered by the outward force applied by the internally pressurizing fluid (typically, diastolically-pressurized blood). These opposing forces jointly retain the fluid flow guide (and thus the entire compliance-restoration body portion 34) at greatest diastolic outer radius RD.
For some applications, when body 22 is in the radially-expanded deployment state: (a) greatest diastolic outer radius RD is at least 7.5 mm, no more than 25 mm, and/or between 7.5 mm and 25 mm, and/or (b) greatest systolic outer radius RS is at least 8.5 mm, no more than 30 mm, and/or between 8.5 mm and 30 mm.
As mentioned above, the graft material of fluid flow guide 26 is generally non- or minimally-elastic. Therefore, when compliance-restoration body portion 34 is internally pressured by diastolic pressure, and is thus characterized greatest diastolic outer radius RD (which is less than maximum greatest outer radius RM of fluid flow guide 26), the graft material of the compliance-restoration portion is at least partially folded. In other words, during diastole, the outer radius of compliance-restoration body portion 34 is less than the maximum outer radius of the fluid flow guide (though the actual circumference of the fluid flow guide remains essentially the same, so the graft material of the fluid flow guide must assume small folds to accommodate this state). (The actual circumference is to be understood as measuring the actual length of the fabric's wall if the fabric were to be flattened to remove any folds, invaginations, or bulges caused by the radial contraction of the fluid flow guide.)
Fluid flow guide 26, if not attached to stent member 24 (e.g., before completion of manufacture of stent-graft 20), is configured to assume first and second perimeters when internally pressurized by fluid having a pressure of 80 and 120 mmHg, respectively. For some applications, the second perimeter is no more than 10% greater than the first perimeter, such as no more than 5% greater than the first perimeter. Alternatively or additionally, for some applications, the second perimeter is between 0.5% and 5% greater than the first perimeter.
For some applications, body 22 further includes distal and proximal portions 40 and 42, longitudinally between which compliance-restoration body portion 34 is disposed. When body 22 is in the radially-expanded deployment state, distal and proximal portions 40 and 42 are:
For some applications, greatest systolic distal-end-portion outer radius RDS is less than 2% greater than greatest diastolic distal-end-portion outer radius RDD, and/or greatest systolic proximal-end-portion outer radius RPS is less than 2% greater than greatest diastolic proximal-end-portion outer radius RPD. In other words, the radii of distal and proximal portions 40 and 42 change only slightly, or not at all, during the transition between diastole and systole. (In contrast, the outer radius of compliance-restoration body portion 34 changes substantially (e.g., by at least 5%), during the transition between diastole and systole, as described above.)
Reference is still made to
In a first configuration, as shown in
In a second configuration, as shown in
In a third configuration (not shown), stent-graft 20 is configured such that:
Reference is now made to
In
In
In
Reference is again made to
Reference is now made to
In this configuration, stent-graft 20 is configured such that:
In addition, greatest systolic outer radius RS is greater than greatest diastolic outer radius RD (e.g., at least 3% greater than, such as at least 5% greater than). For some applications, each of greatest unconstrained distal- and proximal-end-portion radii RDU and RPU is at least 5 mm, no more than 20 mm, and/or between 10 and 30 mm, e.g., at least 11 mm, no more than 25 mm, and/or between 11 and 25 mm.
In this configuration, endovascular stent-graft 20 may be deployed in an aneurysmatic blood vessel, such as an aneurysmatic aorta, such as described hereinabove with reference to
Reference is now made to
In contrast, conventional stents-grafts that comprise polyethylene terephthalate (PET) or polytetrafluoroethylene (ePTFE, available under the trademark Gore-Tex®) maintain approximately 100% and 95%, respectively, of their maximum graft caliber as internal pressure varies in a physiologically-normal range. It is noted that even conventional stent-grafts that comprise graft material that allows a 5% change in graft caliber cannot increase by at least 5% in radius, because the stent elements of conventional stent-grafts are heat-set to hold the stent-graft in its maximum graft caliber even when not pressurized by physiological blood pressure from the inside.
Reference is now made to
Reference is made to
Variable-length section 120, while radially-expanded in the deployment state, is configured to enable a change in an axial length thereof of at least 5 mm, such as at least 8 mm, e.g., at least 10 mm, and/or no more than 30 mm, e.g., no more than 25 mm. Alternatively or additionally, variable-length section 120 is configured such that the enabled change in the axial length is equal to at least 10%, e.g., at least 20%, and/or no more than 30%, e.g., no more than 10%, of outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state (“greatest diameter” means the diameter at the longitudinal site having the greatest diameter). It is noted that even though the entire length of the stent-graft somewhat changes as the length of the variable-length section changes, the variable-length section should not be construed as including the entire length of the stent-graft. Instead, variable-length section 120 is to be understood as being that portion of the stent-graft that actually facilitates the change in axial length, as labeled in
When body 110 is in the radially-expanded deployment state, variable-length section 120 is configured to assume an axially-shortest state thereof. Typically, at least when variable-length section 120 is in this axially-shortest state, one or more of structural stent elements 114 are arranged along the variable-length section such that the variable-length section has no structural-stent-element-free axial portions having axial lengths greater than 5%, e.g., greater than 10%, of greatest outer diameter D of the fluid flow guide along the variable-length section when in its axially-shortest state; for some applications, the variable-length section has no structural-stent-element-free portions when in its axially-shortest state. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.
Fluid flow guide 112 comprises a graft material, i.e., at least one biologically-compatible substantially blood-impervious flexible sheet. The flexible sheet may comprise, for example, a polyester, a polyethylene (e.g., a poly-ethylene-terephthalate), a polymeric film material (such as a fluoropolymer, e.g., polytetrafluoroethylene), a polymeric textile material (e.g., woven polyethylene terephthalate (PET)), natural tissue graft (e.g., saphenous vein or collagen), Polytetrafluoroethylene (PTFE), ePTFE, Dacron, or a combination of two or more of these materials. The graft material optionally is woven. Typically, the graft material is not accordion-pleated. For some applications, structural stent elements 114 comprise a metal. Alternatively or additionally, the structural stent elements comprise a self-expanding material, such that body 110 (and, optionally, stent-graft 90) is self-expandable. Alternatively or additionally, the structural stent elements comprise one or more metallic alloys, such as one or more superelastic metal alloys, a shape memory metallic alloy, and/or Nitinol.
For some applications, as shown in the blow-up in
For some applications, at least one of structural stent elements 114 is attached to second longitudinal subsection 134. Alternatively or additionally, for some applications, at least one of structural stent elements 114 is attached to third longitudinal subsection 136. Further alternatively or additionally, for some applications, an average surface coverage ratio of structural stent elements 114 on fluid flow guide 112 along first subsection 132 is no more than 20%, such as no more than 10%, of the greater of (a) an average surface coverage ratio on fluid flow guide 112 along second longitudinal subsection 134 and (b) an average surface coverage ratio on fluid flow guide 112 along third longitudinal subsection 136. For some applications, variable-length section 120 is configured such that none of structural stent elements 114 of body 110 is attached to first longitudinal subsection 132. This lower average surface coverage ratio (such as no surface coverage) provides greater evertibility to first longitudinal subsection 132, thereby enabling the transition of foldable section 130 from the folded state to the unfolded state. During this transition, first longitudinal subsection 132 is everted, i.e., turned inside-out.
Alternatively or additionally, the average surface coverage ratio of structural stent elements 114 on fluid flow guide 112 along first longitudinal subsection 132 is not necessarily no more than 20%. The greater evertibility of first longitudinal subsection 132 compared to second and third longitudinal subsections 134 and 136 may be provided by:
For some applications, a first subgroup of structural stent elements 114 is attached (e.g., sutured) to second longitudinal subsection 134, and a second subgroup of structural stent elements 114 is attached (e.g., sutured) to third longitudinal subsection 136. For some applications, one of the first and second subgroups of structural stent elements 114 is attached (e.g., sutured) to an internal surface of fluid flow guide 112, and the other of the first and second subgroups is attached (e.g., sutured) to an external surface of fluid flow guide 112.
For some applications, as shown in
For some applications, a surface coverage ratio of the one or more of structural stent elements 114 of variable-length section 120 on fluid flow guide 112 is at least 5%, such as at least 10%, when variable-length section 120 is the axially-shortest state when body 110 is in the radially-expanded deployment state.
For some applications, such as shown in the blow-up of
Reference is now made to
Reference is now made to
Reference is now made to
Variable-length section 120 of stent-grafts 200 and 202 are configured to change length by means of rotation of a proximal end 206 of variable-length section 120 with respect to a distal end 208 of variable-length section 120. Such rotation causes structural elements 114 to twist. Variable-length section 120 shortens as structural elements 114 twist, and the graft material circumferentially folds around the more acutely curved structural elements.
For some applications, variable-length section 120 is configured to cyclically undergo an increase in the axial length that alternates with a decrease in the axial length. For some applications, the length of the variable-length section increase and decreases every heartbeat. For some applications, variable-section 120 shortens during diastole and lengthens during systole.
For some applications, as shown in
For some applications, as shown in
For configurations in which the stent elements protrude radially outward, variable-length section 120 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge 210 at least partially around a perimeter of an axial site on variable-length section 120. Radially-outward bulge 210 comprises the one or more of structural elements 114 of variable-length section 120, and, typically, a portion of the graft material of fluid flow guide 112. Typically, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.
Typically, when variable-length section 120 is in an axially-longest state (for example, as shown in
When body 110 is in the radially-expanded deployment state (as shown in
Reference is made to
For configurations in which the stent elements protrude radially outward, variable-length section 120 is shaped so as to define, at least when the variable-length section is in the axially-shortest state, a radially-outward bulge 310 at least partially around a perimeter of an axial site on variable-length section 120. Radially-outward bulge 310 comprises the one or more of structural elements 114 of variable-length section 120. Typically, the variable-length section is configured such that a radial dimension of the bulge decreases as the axial length of the variable-length section increases. Typically, variable-length section 120 is configured such that structural stent elements 114 thereof do not undergo plastic deformation as the axial length changes.
Bulge 310 radially protrudes less when the variable-length section is in an axially-longer state than when in an axially-shorter state. Typically, variable-length section 120 is relaxed in the axially-shorter state. For some applications, a surface coverage ratio of the one or more of structural stent elements 114 of variable-length section 120 on fluid flow guide 112 is at least 5%, such as at least 10%.
When body 110 is in the radially-expanded deployment state (as shown in
Reference is made to
Reference is again made to
Reference is still made to
Reference is still made to
Reference is still made to
For some applications in which structural stent elements 114 comprises a shape memory alloy, such as Nitinol, the spring-like properties of the alloy enable this repeated change in length of the variable-length section. Typically, variable-length section 120 is configured to undergo (a) an increase in the axial length in response to an increase in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to a decrease in the fluid pressure within the fluid flow guide. Alternatively, variable-length section 120 is configured to undergo (a) an increase in the axial length in response to a decrease in fluid pressure within the fluid flow guide, and (b) a decrease in the axial length in response to an increase in the fluid pressure within the fluid flow guide.
Reference is again made to
Reference is now made to
Stent-graft 400 may implement the configuration of compliance-restoration body portion 34 described hereinabove with reference to
As used in the present application, including in the claims, “tubular” means having the form of an elongated hollow object that defines a conduit therethrough. A “tubular” structure may have varied cross-sections therealong, and the cross-sections are not necessarily circular. For example, one or more of the cross-sections may be generally circular, or generally elliptical but not circular, or circular.
The scope of the present invention includes embodiments described in the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following applications are combined with techniques and apparatus described herein:
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is the US national stage of International Application PCT/IL2012/000148, filed Apr. 4, 2012, which claims priority from US Provisional Application 61/528,242, filed Aug. 28, 2011, and U.S. Provisional Application 61/553,209, filed Oct. 30, 2011, both of which are assigned to the assignee of the present application and are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IL2012/000148 | 4/4/2012 | WO | 00 | 5/13/2014 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2013/030818 | 3/7/2013 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4180613 | Vassiliou | Dec 1979 | A |
| 4355426 | MacGregor | Oct 1982 | A |
| 4505767 | Quin | Mar 1985 | A |
| 4562596 | Kornberg | Jan 1986 | A |
| 4577631 | Kreamer | Mar 1986 | A |
| 4617932 | Kornberg | Oct 1986 | A |
| 4665906 | Jervis | May 1987 | A |
| 4739762 | Palmaz | Apr 1988 | A |
| 4787899 | Lazarus | Nov 1988 | A |
| 4816339 | Tu et al. | Mar 1989 | A |
| 4878906 | Lindemann et al. | Nov 1989 | A |
| 4886062 | Wiktor | Dec 1989 | A |
| 4938740 | Melbin | Jul 1990 | A |
| 4969458 | Wiktor | Nov 1990 | A |
| 5042707 | Taheri | Aug 1991 | A |
| 5064435 | Porter | Nov 1991 | A |
| 5104404 | Wolff | Apr 1992 | A |
| 5122136 | Guglielmi et al. | Jun 1992 | A |
| 5133732 | Wiktor | Jul 1992 | A |
| 5192256 | Ryan | Mar 1993 | A |
| 5192286 | Phan et al. | Mar 1993 | A |
| 5234448 | Wholey et al. | Aug 1993 | A |
| 5383926 | Lock et al. | Jan 1995 | A |
| 5456694 | Marin et al. | Oct 1995 | A |
| 5486183 | Middleman et al. | Jan 1996 | A |
| 5507769 | Marin et al. | Apr 1996 | A |
| 5509923 | Middleman et al. | Apr 1996 | A |
| 5522880 | Barone et al. | Jun 1996 | A |
| 5527322 | Klein et al. | Jun 1996 | A |
| 5549662 | Fordenbacher | Aug 1996 | A |
| 5554181 | Das | Sep 1996 | A |
| 5556413 | Lam | Sep 1996 | A |
| 5562724 | Vorwerk et al. | Oct 1996 | A |
| 5607445 | Summers | Mar 1997 | A |
| 5613974 | Andreas et al. | Mar 1997 | A |
| 5632746 | Middleman et al. | May 1997 | A |
| 5632763 | Glastra | May 1997 | A |
| 5632772 | Alcime et al. | May 1997 | A |
| 5639278 | Dereume et al. | Jun 1997 | A |
| 5643340 | Nunokawa | Jul 1997 | A |
| 5653743 | Martin | Aug 1997 | A |
| 5676696 | Marcade | Oct 1997 | A |
| 5676697 | McDonald | Oct 1997 | A |
| 5693084 | Chuter | Dec 1997 | A |
| 5728134 | Barak | Mar 1998 | A |
| 5749879 | Middleman et al. | May 1998 | A |
| 5755770 | Ravenscroft | May 1998 | A |
| 5755771 | Penn et al. | May 1998 | A |
| 5755774 | Pinchuk | May 1998 | A |
| 5755777 | Chuter | May 1998 | A |
| 5755781 | Jayaraman | May 1998 | A |
| 5769882 | Fogarty et al. | Jun 1998 | A |
| 5769884 | Solovay | Jun 1998 | A |
| 5782903 | Wiktor | Jul 1998 | A |
| 5782906 | Marshall et al. | Jul 1998 | A |
| 5824040 | Cox et al. | Oct 1998 | A |
| 5824055 | Spiridigliozzi et al. | Oct 1998 | A |
| 5827321 | Roubin et al. | Oct 1998 | A |
| 5843170 | Ahn | Dec 1998 | A |
| 5855600 | Alt | Jan 1999 | A |
| 5860991 | Klein et al. | Jan 1999 | A |
| 5876432 | Lau et al. | Mar 1999 | A |
| 5906641 | Thompson et al. | May 1999 | A |
| 5921994 | Andreas et al. | Jul 1999 | A |
| 5925076 | Inoue | Jul 1999 | A |
| 5948018 | Dereume et al. | Sep 1999 | A |
| 5968091 | Pinchuk et al. | Oct 1999 | A |
| 5976178 | Goldsteen et al. | Nov 1999 | A |
| 5980552 | Pinchasik et al. | Nov 1999 | A |
| 5984955 | Wisselink | Nov 1999 | A |
| 6015431 | Thornton et al. | Jan 2000 | A |
| 6016810 | Ravenscroft | Jan 2000 | A |
| 6030414 | Taheri | Feb 2000 | A |
| 6033435 | Penn et al. | Mar 2000 | A |
| 6036723 | Anidjar et al. | Mar 2000 | A |
| 6036725 | Avellanet | Mar 2000 | A |
| 6049824 | Simonin | Apr 2000 | A |
| 6051021 | Frid | Apr 2000 | A |
| 6059824 | Taheri | May 2000 | A |
| 6077298 | Tu et al. | Jun 2000 | A |
| 6099497 | Adams et al. | Aug 2000 | A |
| 6099548 | Taheri | Aug 2000 | A |
| 6117145 | Wood et al. | Sep 2000 | A |
| 6129738 | Lashinski et al. | Oct 2000 | A |
| 6132457 | Chobotov | Oct 2000 | A |
| 6152956 | Pierce | Nov 2000 | A |
| 6156064 | Chouinard | Dec 2000 | A |
| 6159228 | Frid et al. | Dec 2000 | A |
| 6168615 | Ken et al. | Jan 2001 | B1 |
| 6176875 | Lenker et al. | Jan 2001 | B1 |
| 6179878 | Duerig et al. | Jan 2001 | B1 |
| 6200339 | Leschinsky et al. | Mar 2001 | B1 |
| 6206893 | Klein et al. | Mar 2001 | B1 |
| 6270524 | Kim | Aug 2001 | B1 |
| 6283991 | Cox et al. | Sep 2001 | B1 |
| 6287335 | Drasler et al. | Sep 2001 | B1 |
| 6290720 | Khosravi et al. | Sep 2001 | B1 |
| 6296661 | Davila et al. | Oct 2001 | B1 |
| 6312458 | Golds | Nov 2001 | B1 |
| 6325819 | Pavcnik et al. | Dec 2001 | B1 |
| 6325823 | Horzewski et al. | Dec 2001 | B1 |
| 6344056 | Dehdashtian | Feb 2002 | B1 |
| 6395018 | Castaneda | May 2002 | B1 |
| 6406420 | McCarthy et al. | Jun 2002 | B1 |
| 6428565 | Wisselink | Aug 2002 | B1 |
| 6451048 | Berg et al. | Sep 2002 | B1 |
| 6451051 | Drasler et al. | Sep 2002 | B2 |
| 6471722 | Inoue | Oct 2002 | B1 |
| 6506211 | Skubitz et al. | Jan 2003 | B1 |
| 6520988 | Colombo et al. | Feb 2003 | B1 |
| 6544279 | Hopkins et al. | Apr 2003 | B1 |
| 6565597 | Fearnot et al. | May 2003 | B1 |
| 6576009 | Ryan et al. | Jun 2003 | B2 |
| 6613078 | Barone | Sep 2003 | B1 |
| 6635083 | Cheng et al. | Oct 2003 | B1 |
| 6645242 | Quinn | Nov 2003 | B1 |
| 6648901 | Fleischman et al. | Nov 2003 | B2 |
| 6648911 | Sirhan et al. | Nov 2003 | B1 |
| 6652567 | Deaton | Nov 2003 | B1 |
| 6652571 | White et al. | Nov 2003 | B1 |
| 6656214 | Fogarty et al. | Dec 2003 | B1 |
| 6673080 | Reynolds et al. | Jan 2004 | B2 |
| 6692520 | Gambale et al. | Feb 2004 | B1 |
| 6695833 | Frantzen | Feb 2004 | B1 |
| 6695875 | Stelter et al. | Feb 2004 | B2 |
| 6699277 | Freidberg et al. | Mar 2004 | B1 |
| 6716238 | Elliott | Apr 2004 | B2 |
| 6730117 | Tseng et al. | May 2004 | B1 |
| 6733523 | Shaolian et al. | May 2004 | B2 |
| 6743195 | Zucker | Jun 2004 | B2 |
| 6748953 | Sherry et al. | Jun 2004 | B2 |
| 6752826 | Holloway et al. | Jun 2004 | B2 |
| 6776794 | Hong et al. | Aug 2004 | B1 |
| 6808534 | Escano | Oct 2004 | B1 |
| 6814749 | Cox et al. | Nov 2004 | B2 |
| 6814752 | Chuter | Nov 2004 | B1 |
| 6824560 | Pelton | Nov 2004 | B2 |
| 6843803 | Ryan et al. | Jan 2005 | B2 |
| 6846321 | Zucker | Jan 2005 | B2 |
| 6860900 | Clerc et al. | Mar 2005 | B2 |
| 6907285 | Denker et al. | Jun 2005 | B2 |
| 6908477 | McGuckin, Jr. et al. | Jun 2005 | B2 |
| 6929660 | Ainsworth et al. | Aug 2005 | B1 |
| 6942691 | Chuter | Sep 2005 | B1 |
| 6953469 | Ryan | Oct 2005 | B2 |
| 6964679 | Marcade et al. | Nov 2005 | B1 |
| 6986774 | Middleman et al. | Jan 2006 | B2 |
| 7008441 | Zucker | Mar 2006 | B2 |
| 7018400 | Lashinski et al. | Mar 2006 | B2 |
| 7022131 | Derowe et al. | Apr 2006 | B1 |
| 7044962 | Elliott | May 2006 | B2 |
| 7105015 | Goshgarian | Sep 2006 | B2 |
| 7105020 | Greenberg et al. | Sep 2006 | B2 |
| 7112217 | Kugler et al. | Sep 2006 | B1 |
| 7115127 | Lindenbaum et al. | Oct 2006 | B2 |
| 7122052 | Greenhalgh | Oct 2006 | B2 |
| 7131991 | Zarins et al. | Nov 2006 | B2 |
| 7144421 | Carpenter et al. | Dec 2006 | B2 |
| 7160318 | Greenberg et al. | Jan 2007 | B2 |
| 7175651 | Kerr | Feb 2007 | B2 |
| 7198638 | Dong | Apr 2007 | B2 |
| 7201772 | Schwammenthal et al. | Apr 2007 | B2 |
| 7220274 | Quinn | May 2007 | B1 |
| 7223266 | Lindenbaum et al. | May 2007 | B2 |
| 7261733 | Brown et al. | Aug 2007 | B1 |
| 7270675 | Chun et al. | Sep 2007 | B2 |
| 7279003 | Berra et al. | Oct 2007 | B2 |
| 7294145 | Ward | Nov 2007 | B2 |
| 7294147 | Hartley | Nov 2007 | B2 |
| 7306623 | Watson | Dec 2007 | B2 |
| 7341598 | Davidson et al. | Mar 2008 | B2 |
| 7393357 | Stelter et al. | Jul 2008 | B2 |
| 7396363 | Frid | Jul 2008 | B2 |
| 7399313 | Brown et al. | Jul 2008 | B2 |
| 7407509 | Greenberg et al. | Aug 2008 | B2 |
| 7413573 | Hartley et al. | Aug 2008 | B2 |
| 7425219 | Quadri | Sep 2008 | B2 |
| 7429269 | Schwammenthal et al. | Sep 2008 | B2 |
| 7438721 | Doig et al. | Oct 2008 | B2 |
| 7442204 | Schwammenthal et al. | Oct 2008 | B2 |
| 7473272 | Pryor | Jan 2009 | B2 |
| 7491231 | Nazzaro et al. | Feb 2009 | B2 |
| 7537606 | Hartley et al. | May 2009 | B2 |
| 7537609 | Davidson et al. | May 2009 | B2 |
| 7540881 | Meyer et al. | Jun 2009 | B2 |
| 7544160 | Gross | Jun 2009 | B2 |
| 7575590 | Watson | Aug 2009 | B2 |
| 7616997 | Kieval et al. | Nov 2009 | B2 |
| 7637939 | Tischler | Dec 2009 | B2 |
| 7645298 | Hartley et al. | Jan 2010 | B2 |
| 7655036 | Goodson | Feb 2010 | B2 |
| 7655037 | Fleming, III | Feb 2010 | B2 |
| 7662161 | Briganti et al. | Feb 2010 | B2 |
| 7662168 | McGuckin, Jr. et al. | Feb 2010 | B2 |
| 7670369 | Schaeffer | Mar 2010 | B2 |
| 7678141 | Greenan et al. | Mar 2010 | B2 |
| 7699885 | Leonhardt et al. | Apr 2010 | B2 |
| 7708704 | Mitelberg et al. | May 2010 | B2 |
| 7722626 | Middleman et al. | May 2010 | B2 |
| 7731732 | Ken | Jun 2010 | B2 |
| 7766955 | Vardi et al. | Aug 2010 | B2 |
| 7771465 | Zukowski | Aug 2010 | B2 |
| 7789903 | Spiridigliozzi et al. | Sep 2010 | B2 |
| 7803178 | Whirley et al. | Sep 2010 | B2 |
| 7806923 | Moloney | Oct 2010 | B2 |
| 7815673 | Bloom et al. | Oct 2010 | B2 |
| 7833259 | Boatman | Nov 2010 | B2 |
| 7846194 | Hartley et al. | Dec 2010 | B2 |
| 7850725 | Vardi et al. | Dec 2010 | B2 |
| 7867270 | Hartley et al. | Jan 2011 | B2 |
| 7887575 | Kujawski | Feb 2011 | B2 |
| 7914572 | Hartley et al. | Mar 2011 | B2 |
| 7955373 | Sowinski et al. | Jun 2011 | B2 |
| 7955374 | Erickson et al. | Jun 2011 | B2 |
| 7959662 | Erbel et al. | Jun 2011 | B2 |
| 7959669 | Chalekian et al. | Jun 2011 | B2 |
| 7998186 | Hartley | Aug 2011 | B2 |
| 7998187 | Hartley et al. | Aug 2011 | B2 |
| 8012193 | Hartley et al. | Sep 2011 | B2 |
| 8021412 | Hartley et al. | Sep 2011 | B2 |
| 8021418 | Gerberding et al. | Sep 2011 | B2 |
| 8021419 | Hartley et al. | Sep 2011 | B2 |
| 8043365 | Thramann | Oct 2011 | B2 |
| 8048139 | Frid et al. | Nov 2011 | B2 |
| 8048140 | Purdy | Nov 2011 | B2 |
| 8048147 | Adams | Nov 2011 | B2 |
| 8052736 | Doig et al. | Nov 2011 | B2 |
| 8052741 | Bruszewski et al. | Nov 2011 | B2 |
| 8066755 | Zacharias et al. | Nov 2011 | B2 |
| 8080026 | Konstantino et al. | Dec 2011 | B2 |
| 8080053 | Satasiya et al. | Dec 2011 | B2 |
| 8100960 | Bruszewski | Jan 2012 | B2 |
| 8118854 | Bowe | Feb 2012 | B2 |
| 8133267 | Leonhardt et al. | Mar 2012 | B2 |
| 8157810 | Case et al. | Apr 2012 | B2 |
| 8167926 | Hartley et al. | May 2012 | B2 |
| 8172892 | Chuter et al. | May 2012 | B2 |
| 8172895 | Anderson et al. | May 2012 | B2 |
| 8197475 | Bruszewski et al. | Jun 2012 | B2 |
| 8197533 | Kujawski | Jun 2012 | B2 |
| 8211158 | Wolf | Jul 2012 | B2 |
| 8216298 | Wright et al. | Jul 2012 | B2 |
| 8221494 | Schreck et al. | Jul 2012 | B2 |
| 8226706 | Hartley et al. | Jul 2012 | B2 |
| 8236040 | Mayberry et al. | Aug 2012 | B2 |
| 8251963 | Chin et al. | Aug 2012 | B2 |
| 8257423 | Kerr | Sep 2012 | B2 |
| 8262719 | Erickson et al. | Sep 2012 | B2 |
| 8273115 | Hamer et al. | Sep 2012 | B2 |
| 8287586 | Schaeffer et al. | Oct 2012 | B2 |
| 8292885 | Bruszewski et al. | Oct 2012 | B2 |
| 8292941 | Muzslay | Oct 2012 | B2 |
| 8292949 | Berra et al. | Oct 2012 | B2 |
| 8292951 | Muzslay | Oct 2012 | B2 |
| 8333800 | Bruszewski et al. | Dec 2012 | B2 |
| 8337546 | Bruszewski | Dec 2012 | B2 |
| 8353898 | Lutze et al. | Jan 2013 | B2 |
| 8357192 | Mayberry et al. | Jan 2013 | B2 |
| 8361134 | Hartley et al. | Jan 2013 | B2 |
| 8394136 | Hartley et al. | Mar 2013 | B2 |
| 8425585 | Melsheimer et al. | Apr 2013 | B2 |
| 8470018 | Hartley et al. | Jun 2013 | B2 |
| 8475513 | Sithian | Jul 2013 | B2 |
| 8480726 | Cunningham et al. | Jul 2013 | B2 |
| 8491646 | Schreck | Jul 2013 | B2 |
| 8506622 | Bruszewski et al. | Aug 2013 | B2 |
| 20010000188 | Lenker et al. | Apr 2001 | A1 |
| 20010004705 | Killion et al. | Jun 2001 | A1 |
| 20010010006 | Bachinski et al. | Jul 2001 | A1 |
| 20010014823 | Ressemann et al. | Aug 2001 | A1 |
| 20010034550 | Buirge et al. | Oct 2001 | A1 |
| 20010037142 | Stelter et al. | Nov 2001 | A1 |
| 20010044647 | Pinchuk et al. | Nov 2001 | A1 |
| 20010044651 | Steinke et al. | Nov 2001 | A1 |
| 20010044652 | Moore | Nov 2001 | A1 |
| 20010047198 | Drasler et al. | Nov 2001 | A1 |
| 20010049550 | Martin et al. | Dec 2001 | A1 |
| 20010053930 | Kugler et al. | Dec 2001 | A1 |
| 20020040236 | Lau et al. | Apr 2002 | A1 |
| 20020052643 | Wholey et al. | May 2002 | A1 |
| 20020052644 | Shaolian et al. | May 2002 | A1 |
| 20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
| 20020099438 | Furst | Jul 2002 | A1 |
| 20020099441 | Dehdashtian | Jul 2002 | A1 |
| 20020107564 | Cox et al. | Aug 2002 | A1 |
| 20020111667 | Girton et al. | Aug 2002 | A1 |
| 20020123791 | Harrison | Sep 2002 | A1 |
| 20020156495 | Brenneman et al. | Oct 2002 | A1 |
| 20020156517 | Perouse | Oct 2002 | A1 |
| 20020173809 | Fleischman et al. | Nov 2002 | A1 |
| 20020183783 | Shadduck | Dec 2002 | A1 |
| 20020193864 | Khosravi et al. | Dec 2002 | A1 |
| 20020198585 | Wisselink | Dec 2002 | A1 |
| 20030033005 | Houser et al. | Feb 2003 | A1 |
| 20030040791 | Oktay | Feb 2003 | A1 |
| 20030057156 | Peterson et al. | Mar 2003 | A1 |
| 20030065386 | Weadock | Apr 2003 | A1 |
| 20030074055 | Haverkost | Apr 2003 | A1 |
| 20030093145 | Lawrence-Brown et al. | May 2003 | A1 |
| 20030114061 | Matsuda et al. | Jun 2003 | A1 |
| 20030125796 | Dong | Jul 2003 | A1 |
| 20030130720 | DePalma et al. | Jul 2003 | A1 |
| 20030139802 | Wulfman et al. | Jul 2003 | A1 |
| 20030144725 | Lombardi | Jul 2003 | A1 |
| 20030153944 | Phung et al. | Aug 2003 | A1 |
| 20030153968 | Geis et al. | Aug 2003 | A1 |
| 20030163187 | Weber | Aug 2003 | A1 |
| 20030171771 | Anderson et al. | Sep 2003 | A1 |
| 20030191523 | Hojeibane | Oct 2003 | A1 |
| 20030199967 | Hartley et al. | Oct 2003 | A1 |
| 20030199968 | Ainsworth et al. | Oct 2003 | A1 |
| 20030204236 | Letort | Oct 2003 | A1 |
| 20030204242 | Zarins et al. | Oct 2003 | A1 |
| 20030204243 | Shiu | Oct 2003 | A1 |
| 20030212449 | Cox | Nov 2003 | A1 |
| 20030233117 | Adams et al. | Dec 2003 | A1 |
| 20030236567 | Elliot | Dec 2003 | A1 |
| 20040015227 | Vardi et al. | Jan 2004 | A1 |
| 20040015229 | Fulkerson et al. | Jan 2004 | A1 |
| 20040098091 | Erbel et al. | May 2004 | A1 |
| 20040106972 | Deaton | Jun 2004 | A1 |
| 20040106978 | Greenberg et al. | Jun 2004 | A1 |
| 20040117003 | Ouriel et al. | Jun 2004 | A1 |
| 20040133266 | Clerc et al. | Jul 2004 | A1 |
| 20040138735 | Shaolian et al. | Jul 2004 | A1 |
| 20040162606 | Thompson | Aug 2004 | A1 |
| 20040171978 | Shalaby | Sep 2004 | A1 |
| 20040176832 | Hartley et al. | Sep 2004 | A1 |
| 20040181149 | Langlotz et al. | Sep 2004 | A1 |
| 20040215319 | Berra et al. | Oct 2004 | A1 |
| 20040215327 | Doig et al. | Oct 2004 | A1 |
| 20040215332 | Frid | Oct 2004 | A1 |
| 20040260383 | Stelter et al. | Dec 2004 | A1 |
| 20050010246 | Streeter et al. | Jan 2005 | A1 |
| 20050033406 | Barnhart et al. | Feb 2005 | A1 |
| 20050049678 | Cocks et al. | Mar 2005 | A1 |
| 20050065545 | Wallace | Mar 2005 | A1 |
| 20050070995 | Zilla et al. | Mar 2005 | A1 |
| 20050085900 | Case et al. | Apr 2005 | A1 |
| 20050102018 | Carpenter et al. | May 2005 | A1 |
| 20050102021 | Osborne | May 2005 | A1 |
| 20050131517 | Hartley et al. | Jun 2005 | A1 |
| 20050137682 | Justino | Jun 2005 | A1 |
| 20050143802 | Soykan et al. | Jun 2005 | A1 |
| 20050149166 | Schaeffer et al. | Jul 2005 | A1 |
| 20050154448 | Cully et al. | Jul 2005 | A1 |
| 20050159803 | Lad et al. | Jul 2005 | A1 |
| 20050165480 | Jordan et al. | Jul 2005 | A1 |
| 20050171598 | Schaeffer | Aug 2005 | A1 |
| 20050171599 | White | Aug 2005 | A1 |
| 20050177132 | Lentz et al. | Aug 2005 | A1 |
| 20050203606 | VanCamp | Sep 2005 | A1 |
| 20050216018 | Sennett | Sep 2005 | A1 |
| 20050222649 | Capuano et al. | Oct 2005 | A1 |
| 20050222667 | Hunt | Oct 2005 | A1 |
| 20050222668 | Schaeffer et al. | Oct 2005 | A1 |
| 20050222669 | Purdy | Oct 2005 | A1 |
| 20050228480 | Douglas et al. | Oct 2005 | A1 |
| 20050234542 | Melsheimer | Oct 2005 | A1 |
| 20050266042 | Tseng | Dec 2005 | A1 |
| 20050273155 | Bahler et al. | Dec 2005 | A1 |
| 20050283188 | Loshakove et al. | Dec 2005 | A1 |
| 20060015170 | Jones et al. | Jan 2006 | A1 |
| 20060030921 | Chu | Feb 2006 | A1 |
| 20060052799 | Middleman et al. | Mar 2006 | A1 |
| 20060069426 | Weinberger | Mar 2006 | A1 |
| 20060095104 | Magers et al. | May 2006 | A1 |
| 20060095114 | Hartley et al. | May 2006 | A1 |
| 20060100684 | Elliott | May 2006 | A1 |
| 20060106406 | Weinberger | May 2006 | A1 |
| 20060116748 | Kaplan et al. | Jun 2006 | A1 |
| 20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
| 20060155358 | LaDuca et al. | Jul 2006 | A1 |
| 20060155359 | Watson | Jul 2006 | A1 |
| 20060155366 | LaDuca et al. | Jul 2006 | A1 |
| 20060167476 | Burdulis et al. | Jul 2006 | A1 |
| 20060173530 | Das | Aug 2006 | A1 |
| 20060190070 | Dieck et al. | Aug 2006 | A1 |
| 20060193892 | Furst et al. | Aug 2006 | A1 |
| 20060229709 | Morris et al. | Oct 2006 | A1 |
| 20060241740 | Vardi et al. | Oct 2006 | A1 |
| 20060271166 | Thill et al. | Nov 2006 | A1 |
| 20060276882 | Case et al. | Dec 2006 | A1 |
| 20060281966 | Peacock, III | Dec 2006 | A1 |
| 20070016281 | Melsheimer | Jan 2007 | A1 |
| 20070021822 | Boatman | Jan 2007 | A1 |
| 20070043425 | Hartley et al. | Feb 2007 | A1 |
| 20070050011 | Klein et al. | Mar 2007 | A1 |
| 20070055326 | Farley et al. | Mar 2007 | A1 |
| 20070055350 | Erickson et al. | Mar 2007 | A1 |
| 20070055358 | Krolik et al. | Mar 2007 | A1 |
| 20070055360 | Hanson et al. | Mar 2007 | A1 |
| 20070060989 | Deem et al. | Mar 2007 | A1 |
| 20070061002 | Paul, Jr. et al. | Mar 2007 | A1 |
| 20070067014 | Ke et al. | Mar 2007 | A1 |
| 20070073373 | Bonsignore | Mar 2007 | A1 |
| 20070088425 | Schaeffer | Apr 2007 | A1 |
| 20070112344 | Keilman | May 2007 | A1 |
| 20070135677 | Miller et al. | Jun 2007 | A1 |
| 20070142896 | Anderson et al. | Jun 2007 | A1 |
| 20070150051 | Arnault de la Menardiere et al. | Jun 2007 | A1 |
| 20070156167 | Connors et al. | Jul 2007 | A1 |
| 20070162104 | Frid | Jul 2007 | A1 |
| 20070167898 | Peters et al. | Jul 2007 | A1 |
| 20070167955 | Arnault de la Menardiere et al. | Jul 2007 | A1 |
| 20070168013 | Douglas | Jul 2007 | A1 |
| 20070168018 | Amplatz et al. | Jul 2007 | A1 |
| 20070179598 | Duerig | Aug 2007 | A1 |
| 20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
| 20070207186 | Scanlon et al. | Sep 2007 | A1 |
| 20070208410 | Berra et al. | Sep 2007 | A1 |
| 20070213805 | Schaeffer et al. | Sep 2007 | A1 |
| 20070213807 | Roubin et al. | Sep 2007 | A1 |
| 20070219610 | Israel | Sep 2007 | A1 |
| 20070219627 | Chu et al. | Sep 2007 | A1 |
| 20070225797 | Krivoruhko | Sep 2007 | A1 |
| 20070233229 | Berra et al. | Oct 2007 | A1 |
| 20070237973 | Purdy et al. | Oct 2007 | A1 |
| 20070239256 | Weber et al. | Oct 2007 | A1 |
| 20070244542 | Greenan et al. | Oct 2007 | A1 |
| 20070244543 | Mitchell | Oct 2007 | A1 |
| 20070244547 | Greenan | Oct 2007 | A1 |
| 20070250154 | Greenberg et al. | Oct 2007 | A1 |
| 20070255388 | Rudakov et al. | Nov 2007 | A1 |
| 20080033527 | Nunez et al. | Feb 2008 | A1 |
| 20080064957 | Spence | Mar 2008 | A1 |
| 20080109058 | Greenberg et al. | May 2008 | A1 |
| 20080109066 | Quinn | May 2008 | A1 |
| 20080114444 | Yu | May 2008 | A1 |
| 20080114445 | Melsheimer et al. | May 2008 | A1 |
| 20080147173 | Mciff et al. | Jun 2008 | A1 |
| 20080167704 | Wright et al. | Jul 2008 | A1 |
| 20080176271 | Silver et al. | Jul 2008 | A1 |
| 20080195190 | Bland et al. | Aug 2008 | A1 |
| 20080195191 | Luo et al. | Aug 2008 | A1 |
| 20080215134 | Lawrence-Brown | Sep 2008 | A1 |
| 20080249598 | Sherry | Oct 2008 | A1 |
| 20080262595 | Chu et al. | Oct 2008 | A1 |
| 20080262598 | Elmaleh | Oct 2008 | A1 |
| 20080269789 | Eli | Oct 2008 | A1 |
| 20080275540 | Wen | Nov 2008 | A1 |
| 20080275542 | LaDuca et al. | Nov 2008 | A1 |
| 20080288044 | Osborne | Nov 2008 | A1 |
| 20080294234 | Hartley et al. | Nov 2008 | A1 |
| 20080300665 | Lootz et al. | Dec 2008 | A1 |
| 20080319528 | Yribarren et al. | Dec 2008 | A1 |
| 20090012597 | Doig et al. | Jan 2009 | A1 |
| 20090012602 | Quadri | Jan 2009 | A1 |
| 20090030497 | Metcalf et al. | Jan 2009 | A1 |
| 20090030502 | Sun et al. | Jan 2009 | A1 |
| 20090048663 | Greenberg | Feb 2009 | A1 |
| 20090054967 | Das | Feb 2009 | A1 |
| 20090062899 | Dang et al. | Mar 2009 | A1 |
| 20090069881 | Chalekian et al. | Mar 2009 | A1 |
| 20090069882 | Venturelli et al. | Mar 2009 | A1 |
| 20090082841 | Zacharias et al. | Mar 2009 | A1 |
| 20090082847 | Zacharias et al. | Mar 2009 | A1 |
| 20090099648 | Yu | Apr 2009 | A1 |
| 20090099649 | Chobotov et al. | Apr 2009 | A1 |
| 20090099650 | Bolduc et al. | Apr 2009 | A1 |
| 20090105809 | Lee et al. | Apr 2009 | A1 |
| 20090112233 | Xiao | Apr 2009 | A1 |
| 20090125096 | Chu et al. | May 2009 | A1 |
| 20090138067 | Pinchuk et al. | May 2009 | A1 |
| 20090149877 | Hanson et al. | Jun 2009 | A1 |
| 20090157014 | Osborne et al. | Jun 2009 | A1 |
| 20090164001 | Biggs et al. | Jun 2009 | A1 |
| 20090171437 | Brocker et al. | Jul 2009 | A1 |
| 20090192587 | Frid | Jul 2009 | A1 |
| 20090227997 | Wang et al. | Sep 2009 | A1 |
| 20090240316 | Bruszewski | Sep 2009 | A1 |
| 20090248134 | Dierking et al. | Oct 2009 | A1 |
| 20090254170 | Hartley et al. | Oct 2009 | A1 |
| 20090259290 | Bruszewski et al. | Oct 2009 | A1 |
| 20090287145 | Cragg et al. | Nov 2009 | A1 |
| 20100004728 | Rao et al. | Jan 2010 | A1 |
| 20100029608 | Finley et al. | Feb 2010 | A1 |
| 20100057186 | West et al. | Mar 2010 | A1 |
| 20100063575 | Shalev et al. | Mar 2010 | A1 |
| 20100070019 | Shalev | Mar 2010 | A1 |
| 20100082091 | Berez et al. | Apr 2010 | A1 |
| 20100161025 | Kuppurathanam et al. | Jun 2010 | A1 |
| 20100161026 | Brocker et al. | Jun 2010 | A1 |
| 20100211159 | Schmid et al. | Aug 2010 | A1 |
| 20100249899 | Chuter et al. | Sep 2010 | A1 |
| 20100256725 | Rasmussen | Oct 2010 | A1 |
| 20100274187 | Argentine | Oct 2010 | A1 |
| 20100274345 | Rust | Oct 2010 | A1 |
| 20100292774 | Shalev | Nov 2010 | A1 |
| 20100318171 | Porter et al. | Dec 2010 | A1 |
| 20110022149 | Cox et al. | Jan 2011 | A1 |
| 20110022153 | Schreck | Jan 2011 | A1 |
| 20110093002 | Rucker et al. | Apr 2011 | A1 |
| 20110125251 | Cottone et al. | May 2011 | A1 |
| 20110152998 | Berez et al. | Jun 2011 | A1 |
| 20110208289 | Shalev | Aug 2011 | A1 |
| 20110208296 | Duffy et al. | Aug 2011 | A1 |
| 20110208297 | Tuval et al. | Aug 2011 | A1 |
| 20110208298 | Tuval et al. | Aug 2011 | A1 |
| 20110218607 | Arbefeuille et al. | Sep 2011 | A1 |
| 20110218609 | Chobotov | Sep 2011 | A1 |
| 20110257720 | Peterson et al. | Oct 2011 | A1 |
| 20110257725 | Argentine et al. | Oct 2011 | A1 |
| 20110262684 | Wintsch et al. | Oct 2011 | A1 |
| 20110264184 | Heltai | Oct 2011 | A1 |
| 20110288622 | Chan et al. | Nov 2011 | A1 |
| 20110301702 | Rust et al. | Dec 2011 | A1 |
| 20110319983 | Zhu et al. | Dec 2011 | A1 |
| 20120143317 | Cam et al. | Jun 2012 | A1 |
| 20120150274 | Shalev et al. | Jun 2012 | A1 |
| 20120158038 | Leschinsky | Jun 2012 | A1 |
| 20120172929 | Shalev | Jul 2012 | A1 |
| 20120179236 | Benary et al. | Jul 2012 | A1 |
| 20120185031 | Ryan et al. | Jul 2012 | A1 |
| 20120271401 | Bruszewski et al. | Oct 2012 | A1 |
| 20120310324 | Benary et al. | Dec 2012 | A1 |
| 20120316634 | Shalev et al. | Dec 2012 | A1 |
| 20120323305 | Benary et al. | Dec 2012 | A1 |
| 20120330399 | Shalev et al. | Dec 2012 | A1 |
| 20130013050 | Shalev et al. | Jan 2013 | A1 |
| 20130013051 | Benary | Jan 2013 | A1 |
| 20130035751 | Shalev | Feb 2013 | A1 |
| 20130090722 | Shalev et al. | Apr 2013 | A1 |
| 20130131783 | Shalev et al. | May 2013 | A1 |
| 20130204343 | Shalev | Aug 2013 | A1 |
| 20130261994 | Raz et al. | Oct 2013 | A1 |
| 20130274866 | Cox et al. | Oct 2013 | A1 |
| 20130289587 | Shalev | Oct 2013 | A1 |
| 20130297005 | Shalev | Nov 2013 | A1 |
| 20140052236 | Shalev | Feb 2014 | A1 |
| 20140172072 | Shalev | Jun 2014 | A1 |
| 20140288635 | Shalev | Sep 2014 | A1 |
| 20140324154 | Shalev | Oct 2014 | A1 |
| 20140364930 | Strauss et al. | Dec 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 2497704 | Mar 2004 | CA |
| 2453960 | Oct 2001 | CN |
| 2817770 | Sep 2006 | CN |
| 201058061 | May 2008 | CN |
| 1177780 | Feb 2002 | EP |
| 1325716 | Jul 2003 | EP |
| 1470797 | Oct 2004 | EP |
| 1759666 | Mar 2007 | EP |
| 1961401 | Aug 2008 | EP |
| 2266509 | Dec 2010 | EP |
| 2298248 | Mar 2011 | EP |
| 2002253682 | Sep 2002 | JP |
| 9806355 | Feb 1998 | WO |
| 9934748 | Jul 1999 | WO |
| 0028923 | May 2000 | WO |
| 02083038 | Oct 2002 | WO |
| 03099108 | Dec 2003 | WO |
| 2004017868 | Mar 2004 | WO |
| 2005002466 | Jan 2005 | WO |
| 2005034809 | Apr 2005 | WO |
| 2005037138 | Apr 2005 | WO |
| 2005041781 | May 2005 | WO |
| 2005041783 | May 2005 | WO |
| 2005046524 | May 2005 | WO |
| 2006007389 | Jan 2006 | WO |
| 2006028925 | Mar 2006 | WO |
| 2006070372 | Jul 2006 | WO |
| 2007022495 | Feb 2007 | WO |
| 2007039587 | Apr 2007 | WO |
| 2007084547 | Jul 2007 | WO |
| 2007144782 | Dec 2007 | WO |
| 2008008291 | Jan 2008 | WO |
| 2008035337 | Mar 2008 | WO |
| 2008042266 | Apr 2008 | WO |
| 2008047092 | Apr 2008 | WO |
| 2008047354 | Apr 2008 | WO |
| 2008053469 | May 2008 | WO |
| 2008066923 | Jun 2008 | WO |
| 2008107885 | Sep 2008 | WO |
| 2008140796 | Nov 2008 | WO |
| 2009078010 | Jun 2009 | WO |
| 2009116041 | Sep 2009 | WO |
| 2009116042 | Sep 2009 | WO |
| 2009118733 | Oct 2009 | WO |
| 2010024869 | Mar 2010 | WO |
| 2010024879 | Mar 2010 | WO |
| 2010031060 | Mar 2010 | WO |
| 2010045238 | Apr 2010 | WO |
| 2010062355 | Jun 2010 | WO |
| 2010088776 | Aug 2010 | WO |
| 2010128162 | Nov 2010 | WO |
| 2010150208 | Dec 2010 | WO |
| 2011004374 | Jan 2011 | WO |
| 2011007354 | Jan 2011 | WO |
| 2011055364 | May 2011 | WO |
| 2011064782 | Jun 2011 | WO |
| 2011067764 | Jun 2011 | WO |
| 2011070576 | Jun 2011 | WO |
| 2011080738 | Jul 2011 | WO |
| 2011095979 | Aug 2011 | WO |
| 2011106532 | Sep 2011 | WO |
| 2011106533 | Sep 2011 | WO |
| 2011106544 | Sep 2011 | WO |
| 2012049679 | Apr 2012 | WO |
| 2012104842 | Aug 2012 | WO |
| 2012111006 | Aug 2012 | WO |
| 2012117395 | Sep 2012 | WO |
| 2012176187 | Dec 2012 | WO |
| 2013005207 | Jan 2013 | WO |
| 2013030818 | Mar 2013 | WO |
| 2013030819 | Mar 2013 | WO |
| 2013065040 | May 2013 | WO |
| 2013084235 | Jun 2013 | WO |
| 2013171730 | Nov 2013 | WO |
| 2014020609 | Feb 2014 | WO |
| 2014108895 | Jul 2014 | WO |
| 2014141232 | Sep 2014 | WO |
| 2014188412 | Nov 2014 | WO |
| Entry |
|---|
| Communication dated Jul. 2, 2014 from the State Intellectual Property Office of the P.R.C. in counterpart application No. 201080062714.5. |
| Invitation to Pay Additional Fees dated Aug. 27, 2014 from the International Searching Authority in counterpart International Application No. PCT/IL14/50434. |
| Communication dated Nov. 26, 2014 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/383,128. |
| Communication dated Jan. 16, 2015 from the State Intellectual Property Office of the P.R.C. in counterpart application No. 201080062714.5. |
| Communication dated Feb. 3, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 12/447,684. |
| Communication dated Feb. 26, 2015 from the European Patent Office in counterpart application No. 12806964.8. |
| Communication dated Mar. 20, 2015 from the European Patent Office in counterpart application No. 08861980.4. |
| Communication dated Apr. 22, 2015 from the European Patent Office in counterpart application No. 12828495.7. |
| Communication dated May 15, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/577,161. |
| International Search Report and Written Opinion dated Jul. 30, 2014 from the International Searching Authority in counterpart International Application No. PCT/IL14/50174. |
| A non-final Office Action dated Feb. 28, 2014 in U.S. Appl. No. 13/512,778. |
| An International Preliminary Report on Patentability dated Jan. 7, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000269. |
| An International Preliminary Report on Patentability dated Jan. 4, 2012, which issued during the prosecution of Applicant's PCT/IB2010/052861. |
| An International Preliminary Report on Patentability dated Dec. 23, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000241. |
| An International Preliminary Report on Patentability dated Aug. 6, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000060. |
| An English translation of an Office Action dated Oct. 8, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7. |
| An English translation of an Office Action dated Nov. 28, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0. |
| An English translation of an Office Action dated Jan. 28, 2014, which issued during the prosecution of Chinese Patent Application No. 201080036970.7. |
| An English translation of an Office Action dated May 16, 2014, which issued during the prosecution of Chinese Patent Application No. 200880126889.0. |
| An English translation of an Office Action dated Aug. 25, 2011, which issued during the prosecution of Chinese Patent Application No. 200880014919.9. |
| An English translation of an Office Action dated Feb. 16, 2013, which issued during the prosecution of Chinese Patent Application No. 200880126889.0. |
| An International Preliminary Report on Patentability dated Jan. 10, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000549. |
| An International Preliminary Report on Patentability dated Jan. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000564. |
| A Notice of Allowance dated Aug. 2, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
| An Advisory Action dated Feb. 13, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/807,880. |
| An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000999. |
| An International Preliminary Report on Patentability dated Jun. 5, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001018. |
| An International Preliminary Report on Patentability dated Jun. 10, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050506. |
| A Notice of Allowance issued in U.S. Appl. No. 13/807,906 dated Oct. 10, 2014. |
| A Restriction Requirement dated Jan. 29, 2014, which issued during the prosecution of U.S. Appl. No. 13/519,971. |
| An International Preliminary Report on Patentability dated Jun. 12, 2012, which issued during the prosecution of Applicant's PCT/IL2010/001037. |
| An International Preliminary Report on Patentability dated Mar. 4, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000300. |
| An International Preliminary Report on Patentability dated May 6, 2014, which issued during the prosecution of Applicant's PCT/IL2012/050424. |
| An International Preliminary Report on Patentability dated May 8, 2012, which issued during the prosecution of Applicant's PCT/IL2010/000917. |
| An International Preliminary Report on Patentability dated Nov. 18, 2014, which issued during the prosecution of Applicant's PCT/IL2012/000190. |
| An International Search Report and a Written Opinion both dated Apr. 18, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001037. |
| An International Search Report and a Written Opinion both dated Aug. 4, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000999. |
| An International Search Report and a Written Opinion both dated Aug. 31, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000148. |
| An International Search Report and a Written Opinion both dated Dec. 3, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000564. |
| An International Search Report and a Written Opinion both dated Feb. 4, 2011, which issued during the prosecution of Applicant's PCT/IB2010/052861. |
| An International Search Report and a Written Opinion both dated Jul. 13, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000083. |
| An International Search Report and a Written Opinion both dated Jul. 17, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000095. |
| An International Search Report and a Written Opinion both dated Jun. 14, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050506. |
| An International Search Report and a Written Opinion both dated Jun. 28, 2011, which issued during the prosecution of Applicant's PCT/IL2011/000135. |
| An International Search Report and a Written Opinion both dated Jun. 30, 2009, which issued during the prosecution of Applicant's PCT/IL2008/001621. |
| An International Search Report and a Written Opinion both dated Mar. 10, 2011, which issued during the prosecution of Applicant's PCT/IL2010/000917. |
| An International Search Report and a Written Opinion both dated Mar. 11, 2009, which issued during the prosecution of Applicant's PCT/IL2007/001312. |
| An International Search Report and a Written Opinion both dated Mar. 15, 2013, which issued during the prosecution of Applicant's PCT/IL2012/050424. |
| An International Preliminary Report on Patentability dated Sep. 3, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000095. |
| An International Search Report and a Written Opinion both dated Mar. 30, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001018. |
| An International Search Report and a Written Opinion both dated May 23, 2011, which issued during the prosecution of Applicant's PCT/IL2010/001087. |
| An International Search Report and a Written Opinion both dated Nov. 5, 2010, which issued during the prosecution of Applicant's PCT/IL2010/000549. |
| An International Search Report and a Written Opinion both dated Nov. 27, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000300. |
| An International Search Report and a Written Opinion both dated Oct. 1, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000241. |
| An International Search Report and a Written Opinion both dated Oct. 4, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000269. |
| An International Search Report and a Written Opinion both dated Sep. 6, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000190. |
| An International Search Report and a Written Opinion both dated Apr. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019. |
| An International Search Report dated Jul. 30, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050174. |
| An International Search Report and a Written Opinion both dated Sep. 24, 2012, which issued during the prosecution of Applicant's PCT/IL2012/000060. |
| An International Search Report and a Written Opinion both dated Sep. 29, 2008, which issued during the prosecution of Applicant's PCT/IL2008/000287. |
| Notice of allowance dated Jun. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278. |
| An International Search Report dated Nov. 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050434. |
| An Interview Summary dated Feb. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
| An Office Action dated Apr. 10, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/807,906. |
| An Office Action dated Apr. 24, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/380,278. |
| An Office Action dated Dec. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880. |
| An office Action dated Feb. 25, 2013, which issued during the prosecution of U.S. Appl. No. 13/031,871. |
| An Office Action dated Feb. 27, 2013, which issued during the prosecution of U.S. Appl. No. 12/808,037. |
| An Office Action dated Jul. 24, 2014, which issued during the prosecution of Canadian Patent Application No. 2768228. |
| An Office Action dated Jul. 28, 2014, which issued during the prosecution of U.S. Appl. No. 13/031,871. |
| An Office Action dated Jun. 19, 2012, which issued during the prosecution of U.S. Appl. No. 12/808,037. |
| An Office Action dated Mar. 24, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
| An Office Action dated Mar. 28, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/519,971. |
| An Office Action dated Apr. 27, 2011, which issued during the prosecution of U.S. Appl. No. 12/447,684. |
| An Office Action dated Apr. 28, 2014, which issued during the prosecution of Applicant's U.S. Appl. No. 13/939,798. |
| An Office Action dated May 20, 2013, which issued during the prosecution of U.S. Appl. No. 13/807,880. |
| An Office Action dated Nov. 12, 2010, which issued during the prosecution of U.S. Appl. No. 12/447,684. |
| An Office Action dated Nov. 3, 2014, which issued during the prosecution of Canadian Patent Application No. 2767596. |
| An Office Action dated Nov. 19, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,117. |
| An Office Action dated Oct. 11, 2012, which issued during the prosecution of U.S. Appl. No. 13/031,871. |
| U.S. Appl. No. 61/219,758, filed Jun. 23, 2009. |
| U.S. Appl. No. 61/221,074, filed Jun. 28, 2009. |
| U.S. Appl. No. 61/496,613, filed Jun. 14, 2011. |
| An Office Action dated Oct. 28, 2011, which issued during the prosecution of U.S. Appl. No. 12/529,936. |
| U.S. Appl. No. 61/505,132, filed Jul. 7, 2011. |
| U.S. Appl. No. 61/678,182, filed Aug. 1, 2012. |
| U.S. Appl. No. 61/529,931, filed Sep. 1, 2011. |
| U.S. Appl. No. 61/553,209, filed Oct. 30, 2011. |
| U.S. Appl. No. 61/499,195, filed Jun. 21, 2011. |
| U.S. Appl. No. 61/749,965, filed Jan. 8, 2013. |
| Notice of Allowance dated Jun. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/523,296. |
| Office Action issued on Oct. 27, 2014 in Canadian Patent Application No. 2,785,953. |
| Ryhanen J., in “Biocompatibility evaluation of nickel-titanium shape memory metal alloy,” Academic Dissertation, Faculty of Medicine, Department of Surgery, University of Oulu, Finland (May 1999). |
| Supplementary European Search Report dated Dec. 13, 2012, which issued during the prosecution of Applicant's European App No. 08719912.1. |
| Supplementary European Search Report dated Feb. 17, 2014, which issued during the prosecution of Applicant's European App No. 12803376.8. |
| Supplementary European Search Report dated Jun. 23, 2014, which issued during the prosecution of Applicant's European App No. 12741804.4. |
| An International Search Report and Written Opinion both dated Nov. 26, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050656. |
| “E-vita® open plus” product brochure (JOTEC GmbH, Hechingcn, Germany), 2010. |
| An Office action dated Sep. 4, 2014, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/519,971. |
| European Office Action dated Dec. 17, 2014 in European Patent Application No. 12803376.8. |
| An Office action dated Feb. 5, 2015, from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/384,075. |
| European Search Report dated Feb. 24, 2014 in European Patent Application No. 12803376.8. |
| Fattori et al., Degenerative aneurysm of the descending aorta. Endovascular Treatment. pp. 1-11, 2007, European Association for Cardio-Thoracic Surgery. |
| International Preliminary Report on Patentability dated Jan. 12, 2010 in corresponding International Application No. PCT/IL2008/000287. |
| Fonseca A et al., “Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions,” J Invasive Cardiol 20(1):21-7 (Jan. 2008). |
| Van Prehn J et al., “Oversizing of aortic stent grafts for abdominal aneurysm repair: a systematic review of the benefits and risks,” Eur J Vase Endovase Surg. Jul. 2009:38(I):42-53. Epub May 9, 2009 (abstract only). |
| Invitation to Pay Additional Fees dated May 13, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050019. |
| Invitation to Pay Additional Fees dated May 8, 2014, which issued during the prosecution of Applicant's PCT/IL2014/50174. |
| Khlif H et al., “Contribution to the Improvement of Textile Vascular Prostheses Crimping,” Trends in Applied Sciences Research 6(9):1019-1027 (2011). |
| U.S. Appl. No. 61/775,964, filed Mar. 11, 2013. |
| U.S. Appl. No. 61/826,544, filed May 23, 2013. |
| U.S. Appl. No. 61/906,014, filed Nov. 19, 2013. |
| U.S. Appl. No. 61/926,533, filed Jan. 13, 2014. |
| U.S. Appl. No. 61/528,242, filed Aug. 28, 2011. |
| An English translation of an Office Action dated Mar. 19, 2015, which issued during the prosecution of Chinese Patent Application No. 201080036970.7. |
| A Notice of Allowance dated Jan. 20, 2015, which issued during the prosecution of U.S. Appl. No. 13/383,128. |
| A Notice of Allowance dated Nov. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778. |
| An Office Action dated Aug. 15, 2014, which issued during the prosecution of U.S. Appl. No. 13/512,778. |
| An International Search Report and a Written Opinion both dated Mar. 18, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050973. |
| An Office Action dated Apr. 14, 2015, which issued during the prosecution of U.S. Appl. No. 14/130,213. |
| An International Preliminary Report on Patentability dated Feb. 3, 2015, which issued during the prosecution of Applicant's PCT/IL2013/050656. |
| A Notice of Allowance dated Jan. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/663,117. |
| An Office Action dated Mar. 26, 2015, which issued during the prosecution of U.S. Appl. No. 13/514,240. |
| Communication dated Aug. 12, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/513,397. |
| Communication dated Sep. 23, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/384,075. |
| Communication dated Oct. 2, 2015 from the U.S. Patent and Trademark Office in counterpart U.S. Appl. No. 13/577,161. |
| Communication dated Oct. 27, 2015 from the European Patent Office in counterpart application No. 10835608.0. |
| Number | Date | Country | |
|---|---|---|---|
| 20140324154 A1 | Oct 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61528242 | Aug 2011 | US | |
| 61553209 | Oct 2011 | US |